Successful biotech investors stay on top of the calendar, because they need to be proactive about clinical data and Food and Drug Administration action dates. Regular readers have had an insatiable appetite for
previous biotech catalyst calendars, so here's my latest for 2005. It's not comprehensive, and some of the dates are approximations, but this should give biotech investors a good road map for the upcoming year.
Abgenix ( ABGX), Amgen ( AMGN): ABX-EGF, third-line colon cancer study, second half 2005; Cypress BioScience ( CYPB): Milnacipran, fibromyalgia phase III, third quarter 2005; Genentech ( DNA): Lucentis, age-related macular degeneration phase IIII, third quarter 2005. Avastin, front-line lung cancer phase III, second half 2005; Allos Therapeutics ( ALTH): Efaproxyn, brain metastases from lung cancer phase III, fourth quarter 2005; Telik ( TELK): Telcyta, ovarian non-small-cell lung cancer phase III, fourth quarter 2005; Dendreon ( DNDN): Provenge, prostate cancer phase III, second half/fourth quarter 2005; Pharmacyclics ( PCYC): Xcytrin, brain metastases from lung cancer phase III, second half 2005. Northfield Laboratories ( NFLD): Polyheme, blood substitute trauma phase III, year-end 2005; CancerVax ( CNVX): Canvaxin, melanoma phase III, end of 2005.